- 1 Differences in epidemiology of enteropathogens in children pre- and
- 2 post-rotavirus vaccine introduction in Kilifi, coastal Kenya
- 3
- 4 Charles N. Agoti<sup>1, 2, #</sup>,
- 5 Martin D. Curran<sup>3, 4</sup>,
- 6 Nickson Murunga<sup>1</sup>,
- 7 Moses Ngari<sup>1</sup>,
- 8 Ester Muthumbi<sup>1</sup>,
- 9 Arnold Lambisia<sup>1</sup>,
- 10 Simon DW Frost<sup>5, 6</sup>,
- 11 Barbara Blacklaws<sup>7</sup>,
- 12 D. James Nokes<sup>1, 8</sup>, and
- 13 Lydia N Drumright<sup>9, 10</sup>
- 14

## 15 Author Affiliations

- Epidemiology and Demography Department, KEMRI-Wellcome Trust,
   Kilifi, Kenya.
- 18 2. School of Health and Human Sciences, Pwani University, Kilifi, Kenya.
- 19 3. Public Health England, Cambridge, United Kingdom.
- 20 4. Clinical Microbiology and Public Health Laboratory, Addenbrooke's
- 21 Hospital, Cambridge, United Kingdom.
- Microsoft Research, Building 99, 14820 NE 36<sup>th</sup> St. Redmond, WA 98052,
   USA
- 24 6. Department of Infectious Disease Epidemiology, Faculty of Epidemiology
- 25 and Public Health, London School of Hygiene and Tropical Medicine,
- 26 Keppel St, Bloomsbury, London WC1E 7HT, United Kingdom
- Department of Veterinary Medicine, University of Cambridge, Cambridge,
   United Kingdom.
- 29 8. University of Warwick, Coventry, United Kingdom.
- Department of Medicine, University of Cambridge, Cambridge, United
   Kingdom.
- 32 10. Department of Medicine, University of Washington, Washington, United
- 33 States
- 34

- 35 #Corresponding author
- 36 Contact details: P.O. Box 230, Kilifi-80108, Kenya,
- 37 Email: cnyaigoti@kemri-wellcome.org)

#### 38 **Disclaimers**

- 39 The views expressed in this article are solely those of the authors and not of
- 40 the funders or affiliated institutions.

#### 41 Source (s) of support

- 42 This study was supported by the Cambridge-Africa ALBORADA Research
- 43 Fund.

44

- 45 Word Count
- 46 Abstract (250): 227
- 47 Text (3000): 2931
- 48
- 49 Tables & Figures
- 50 Tables: 2
- 51 Figures: 2
- 52 **Disclosure of relationships and activities**
- 53 Key words: Enteropathogens, RVA, Taqman Array Card, co-infections,
- 54 Kenya, vaccination, children, epidemiology
- 55

## 56 Running head:

- 57 Enteropathogens pre- and post-rotavirus vaccination in Kilifi, Kenya
- 58

#### 59 ABSTRACT

60 Background. In July 2014, Kenya introduced the Rotarix® vaccine into its

61 national immunization program. The impact of this vaccination programme on

62 the local epidemiology of enteropathogens is unclear.

63

64 **Methods.** The TaqMan Array Card (TAC) was used for screening for 28

different enteropathogens in 718 stools from children less than 13 years of

age who presented with diarrhea and were admitted to Kilifi County Hospital,

- 67 coastal Kenya, in 2013 (before vaccine introduction) and in 2016-2018 (after
- 68 vaccine introduction). The differences between pre- and post-Rotarix®
- 69 vaccination periods were examined using univariate and multivariable logistic
- 70 regressions.
- 71

72 **Results.** In 665 specimens (92.6%), one or more enteropathogens were

detected, while in 323 specimens (48.6%), three or more enteropathogens

74 were detected. There was a significant increase in the proportion of samples

containing enteroaggregative Escherichia coli (35.7% vs 45.3%, p=0.014),

76 cytomegalovirus (4.2% vs 9.9%, *p=0.008*), Vibrio cholerae (0.0% vs 2.3%,

77 *p*=0.019), Strongyloides species (0.8% vs 3.6%, *p*=0.048) and Dientamoeba

*fragilis* (2.1% vs 7.8%, *p*=0.004) post-vaccine introduction. Sapovirus

detection decreased significantly (7.6% vs 4.0%, *p=0.030*) post-vaccine

80 introduction. The proportion of samples that tested positive for rotavirus group

A did not statistically differ between the pre- and post-vaccine periods (27.4%

- 82 vs. 23.5%, *p=0.253*).
- 83

84 **Conclusions.** In this setting, the burden of childhood enteropathogen

85 infection was high both pre- and post-rotavirus vaccination introduction, with

- 86 some specific changes in the burden of enteropathogens in hospitalized
- 87 children after rotavirus vaccination introduction.

#### 88 INTRODUCTION

In 2016, there were approximately 446,000 deaths worldwide caused by

- 90 diarrheal illnesses among children <5 years, with the majority occurring in low-
- 91 income countries [1, 2]. Rotavirus group A (RVA) was estimated to be
- 92 responsible for approximately 128,000 of these deaths.
- 93

94 The World Health Organization (WHO) recommended inclusion of RVA

- 95 vaccines in national immunization programs (NIPs) of all countries in 2009.
- 96 Kenya included Rotarix® vaccination in its National Immunization Program [3]
- 97 in July 2014, with doses at 6 and 10 weeks of age. Based on antigen testing,
- 98 Kilifi County Hospital (KCH), Kenya, reported a 57% reduction in rotavirus
- 99 hospitalizations in the first year after vaccine introduction and an 80%
- reduction in the second year among children <5 year-olds [4]. KCH found 64%
- 101 vaccine effectiveness for children aged < 5years [5], which is similar to other

102 low-income settings in sub-Saharan Africa [3, 4], but lower than high-income

- 103 settings [5, 6].
- 104

105 Over 30 enteropathogens can cause diarrhea. In addition to a reduction in 106 RVA-induced diarrhea, a referral hospital in Central Kenya observed a 31% 107 decrease in all-cause diarrheal hospital admissions in the first year and a 58% 108 decrease in the second year [7]. While RVA has clearly been responsible for a 109 large burden of severe diarrheal cases among children <5 years-old, many 110 other enteropathogens contribute to severe diarrheal illness in Kenya [8-11] 111 but their epidemiology, both pre- and post-RVA vaccine introduction, is under-112 studied. Previously, we examined change in prevalence of 5 enteric viruses, 113 including RVA, pre and post RVA vaccination demonstrating an increase in 114 norovirus GII and a decrease in RVA, however this study did not examine all 115 causes of diarrheal illness [12]. 116

117 Through the use of a custom TaqMan Array Card (TAC), this study aimed to 118 compare the epidemiological patterns of 28 different enteropathogens in

119 children < 13 years-old admitted to KCH with diarrhea, pre- and post-RVA

- 120 vaccine introduction.
- 121

#### 122 METHODS

123 Study design and population. KCH is a referral facility that primarily serves 124 residents of Kilifi County, Kenya [13]. From September 2009, a surveillance 125 study of rotavirus was established at KCH pediatric ward targeting children 126 <13 years old who presented with diarrhea (defined as passing three or more 127 loose stools in a 24-hour period) [14]. A single stool specimen was collected 128 within 48 hours of admission and immediately put into -4°C before transferring 129 to the adjoining KEMRI-Wellcome Trust Laboratories for long-term storage at 130 -80°C. The current retrospective analysis targeted samples collected in 2013 131 (pre-vaccine period) and 2016-2018 (post-vaccine period). During these 132 periods, sample collection was interrupted 6 times by healthcare worker 133 strikes; 3 times each pre- and post-vaccine introduction [15]. 134 135 **Sample processing**. Total nucleic acid was extracted from stool using two 136 different approaches. The cador Pathogen 96 QIAcube HT Kit (QIAGEN, 137 Hilden, Germany) with 200 µL liquid or 200 mg solid stool was used on 138 samples from 2013. The QIAamp Fast DNA Stool Mini Kit (QIAGEN, Hilden, 139 Germany) with 200 µL or 200 mg stool after bead-beating and centrifugation 140 to remove debris was used on samples from 2016-2018. An extraction blank 141 was included in every processing batch for quality control. The total nucleic 142 acid extracts (NAE) were stored at -80°C for up to 130 weeks and defrosted 143 once, only for the enteropathogen diagnostics.

144 145

146 spotted with lyophilized target-specific primers and probes was used to detect 147 enteropathogens from the total NAE. The GASTRO v4.0K TAC was designed 148 by MC at Public Health England (PHE), Cambridge, England [16] and 149 manufactured by ThermoFisher, USA. GASTRO v4.0K screened for 28 150 enteropathogens: 12 viruses, 10 bacteria, 5 protozoa and 1 helminth 151 (supplementary Table 1). All TAC targets were validated previously by PHE 152 and include 16S bacterial and 18S RNA as internal controls, and bacteriophage MS2 as an external control. A Rotarix<sup>®</sup> vaccine-specific assav 153 154 targeting the NSP2 gene was included to identify RVA vaccine shedding due 155 to prior vaccination. The molecular probes were labeled at the 5' end with 6-

TaqMan Array Card (TAC) analysis. A custom TaqMan Array Card (TAC)

156 carboxyfluorescein (FAM) reporter dye and NFQ-MGB quencher dye at the 3'157 end [16].

158

159 For each TAC, 8 samples were tested (48-wells per sample). A mix of 60 µL

160 of nuclease-free water, 25 µL of TaqMan Fast Virus 1-Step MasterMix

161 (ThermoFisher, USA) containing ROX reference dye and 15 µL of NAE was

162 prepared and loaded onto the TAC sample portal. TACs were spun twice at

163 1200 rpm for two minutes and sealed. TACs were processed using the

164 Quantistudio-7-Flex Real-time PCR System (Thermofisher, USA). The

thermocycling conditions were; 50°C for 5 minutes followed by 45 cycles of

166 95°C for 1 second and 60°C for 20 seconds. Extraction blanks and no

167 template controls were included once in every 10 runs for quality control.

168

169 Amplification data were analysed by the cycle threshold (Ct) method

170 (QuantiStudio<sup>™</sup>Real-Time PCR software v.1.1). A threshold value of 0.2

171 florescence units was applied to all our analyses and baseline range set to

automatic. The amplification curves for all presumptive positive samples were

173 visually inspected prior to recording them as positive. Pathogen prevalence

was evaluated at three different Ct cut-off levels (<40.0, <35.0 and <30.0).

175

176 **Clinical data.** Data were collected using a standard clinical research form 177 (CRF) entered into an electronic database [17]. The CRF included admission 178 date, discharge date, presenting signs and symptoms, co-morbidities, and 179 discharge diagnosis and outcome. Diarrhea was categorized as acute if the 180 duration <7 days, prolonged if 7-13 days, persistent if 14-28 days, and chronic 181 if >28 days. Diarrheal severity was assessed by Vesikari Clinical Severity 182 Score (VCSS) [18]. All samples were clinically tested for rotavirus using a 183 commercial ELISA antigen detection kit (ProsPeCT, Oxoid, Thermo Scientific. 184 All pediatric admissions were offered HIV testing using two rapid antibody 185 tests according to national guidelines. 186

Analyses. We compared clinical and demographic characteristics of (i)
 included and excluded children and (ii) those recruited pre- and post-RVA
 vaccination using chi-squared analysis and Fisher's exact test for categorical

190 variables and Wilcoxon-rank sum and t-tests for continuous variables. As this

191 was the first use of this TAC in Kenya, we descriptively explored different

lower limits of detection (Ct  $\leq$  30, 35, 40) for a positive result. Using Ct  $\leq$ 35 as

193 the lower limit of detection, pathogen prevalence was calculated as the

194 proportion positive over the total tested with 95% confidence intervals (CI)

195 calculated using the exact method. We assessed differences in pathogen

196 presence in pre-/post-RVA vaccination periods by univariate logistic

197 regression. Any enteropathogen that was marginally different (P<0.1) in

198 univariate analyses, as well as rotavirus (due to epidemiological interest),

199 were included in multivariable logistic regression analyses adjusted for age,

sex, Vesikari score, HIV-status, hospital length of stay (LoS), and fatality.

201 Separate multivariate logistic regression analyses per pathogen were

202 conducted due to the high prevalence of co-infections. The analyses were

203 performed in Stata version 16.1 and R version 3.6.3.

204

#### 205 Ethical considerations

206 Before sample collection, informed written consent was gained from each

207 child's parent/guardian. The Scientific and Ethics Review Unit (SERU) at

208 Kenya Medical Research Institute, Nairobi, approved the study protocol

209 (Protocol #3624).

210

## 211 **RESULTS**

212 **Participant characteristics.** 1,317 KCH pediatric admissions with diarrhea

were eligible for inclusion during study periods (2013, 2016-2018). Of these,

1250 (95%) were unique patients; 718 (57.4%) provided an adequate stool

sample for TAC processing. Children who did and did not have a stool sample

216 were similar except those with a stool sample: (i) were more likely to have

reported vomiting at admission (*p*=0.001); (ii) were hospitalized for longer

218 (mean 5.8 days versus 4.3 days, p < 0.001); (iii) were more likely to have been

discharged alive (p < 0.001); (iv) were more likely to have or have been

220 exposed to HIV (p=0.049); and (v) were less likely to be included in 2017 and

221 2018 than in 2013 and 2016 (p<0.001) (**Table 1**).

222

223 The children who had provided sufficient stool had a median age of 13.3 224 months (IQR: 8.0-23.0). Clinical and demographic characteristics of children 225 from pre- (2013) and post-vaccine (2016-2018) introduction periods (n=718) 226 were similar except that those from the pre-vaccine period were (i) 227 significantly younger (11.5 vs 14.1 months, p=0.004); (ii) less likely to have 228 known HIV exposure, but more likely to have unknown HIV status (p<0.001): 229 and (iii) had a lower median hospital stay (4 vs 5 days, p=0.005) than those 230 from the post-vaccine period (Table 1).

231

232 **Pathogen prevalence.** Of the 718 specimens analyzed by TAC, using a 233 polymerase chain reaction (PCR) cycle threshold cut-off of ≤40.0 Ct (which 234 was considered an appropriate cut-off based on clinical samples from the UK 235 [16, 19]) one or more enteropathogen was detected in 94.0% of the children 236 (n=675). The five most common pathogens at the  $\leq$ 40.0 Ct cut off value were: 237 enteroaggregative Escherichia coli (EAggEC) 44.6%; enterovirus 33.0%; 238 enteropathogenic Escherichia coli (EPEC) 32.3%; RVA 25.1%; and 239 parechovirus 20.8% (Figure 1a). When the limit of detection was lowered to 240 ≤30 Ct (high pathogen burden), 12/28 of detected pathogens decreased in 241 prevalence by a factor of 2 or more (Figure 1c). The largest declines were 242 observed with verotoxogenic E. coli (VTEC) (11 fold), Dientamoeba fragilis 243 (8.3 fold), cytomegalovirus (7.4 fold), Strongyloides spp. (5.0 fold), Salmonella 244 spp. (4.0 fold), Clostridium perfringens/difficile (3.8 fold) and hepatitis E virus 245 (3.0 fold). Only three pathogens, *D. fragilis*, hepatitis E virus, and VTEC, 246 showed a reduction by factor 2 or more when comparing a Ct value of  $\leq 40$ 247 versus  $\leq$  35 as the limit of detection. On average, the prevalence of the 248 detected pathogens decreased by 1.3 fold when the Ct cut-off was lowered 249 from 40.0 to 35.0 (Figure 1b). Notably, even with the most stringent Ct cut-off 250 ( $\leq$ 30), the prevalence of RVA was unaffected: 25.1% (21.9-28.4) at Ct  $\leq$ 40 251 versus 22.3% (19.3-25.5) at Ct ≤30. No samples tested positive for Vibrio 252 parahaemolyticus and Entamoeba histolytica at any Ct detection limit. All 253 subsequent analyses have used the Ct cut-off of  $\leq$  35.0 for all pathogens. 254 Detection above this threshold has previously been considered clinically 255 insignificant or irreproducible in studies from low-income settings [20, 21]. 256

257 Pathogens pre- and post-vaccine initiation. Among the 718 samples, 241 258 (33.6%) were from the pre-vaccine period (2013) and 477 (66.4%) were from 259 the post-vaccine introduction period (2016-2018), (**Table 2**). In univariate 260 logistic regression analyses, cytomegalovirus (4.2% vs 9.9%, OR=2.53, 261 p=0.010), EAggEC (35.7% vs 45.3%, OR=1.49, p=0.009), D. fragilis (2.0% vs 262 7.8%, OR=3.97, p=0.004) and Strongyloides spp. (0.8% vs 3.6%, OR=4,42, 263 p=0.048) all increased in detection from pre- to post-vaccine periods, whereas 264 sapovirus decreased in detection (7.8% vs 4.0%, OR=0.49, p=0.030). 265 266 In multivariable models adjusting for age, Vesikari score, fatality, gender, 267 LOS, and HIV-status, cytomegalovirus (OR=2.81, 95% CI 1.36, 5.81), 268 EAggEC (OR=1.58, 95% CI 1.13, 2.20), D. fragilis (OR=3.90, 95% CI 1.49, 269 10.21), and Strongyloides spp. (OR=4.60, 95% CI 1.03, 20.55) were all 270 detected among significantly more patients in the post-vaccine than in the pre-271 vaccine period. Sapovirus no longer demonstrated a significant difference in 272 cases detected after adjusting for covariates (Table 2). 273 274 No differences were observed in the prevalence of RVA in the hospitalized 275 children in the pre-post-RVA vaccination time-periods. In sub-analyses of 276 rotavirus infection, receipt of RVA vaccine was not associated with rotavirus 277 infection in multiply adjusted models including age (data not shown). Both lack 278 of reduction in RVA prevalence and lack of association with vaccine status 279 were still consistently observed when restricting analyses to children >5 years 280 old. No significant changes were observed for any of the other remaining 281 pathogens. 282 283 **Co-infections.** Only 53 children (7.4%) had no enteropathogens detected. 284 Among the rest (n=665), 148 (22.3%) were mono-infected, while 323 (48.6%) 285 had  $\geq$ 3 pathogens detected. Including all children, 72% (n=517) had  $\geq$ 2 286 enteropathogens detected. Five or more enteropathogens were detected in 84 287 children (11.7%). A greater number of different enteropathogens were 288 detected per child in the post-vaccine compared to pre-vaccine period (mean: 289 2.7 vs 2.3 respectively, *p*=0.0025). 290

#### 291 Characteristics of rotavirus positive samples. The distribution of Ct values

- for RVA positive samples based on the TAC analysis is shown in Figure 2, in
- relation to (a) previous RVA ELISA test result, (b) sample period, (c)
- vaccination status, and (d) age group. We found that the median Ct values
- among older children are significantly lower than those among younger
- children, regardless of the sampling year.
- 297

#### 298 **DISCUSSION**

- 299 Our study shows very high prevalence of enteropathogens among
- 300 hospitalized children with diarrhea, extensive co-infections, and differences in
- 301 pathogen prevalence before and after rotavirus vaccine introduction. In
- 302 addition, we observed no significant difference in RVA prevalence between
- 303 pre- and post-vaccine introduction.
- 304

305 The Global Rotavirus Surveillance Network showed that RVA prevalence 306 decreased in children under 5 years of age from 2008 and 2016 following 307 national introduction of the RVA vaccine across 82 countries, although to a 308 lesser extent among low-income countries [24]. Using controlled interrupted 309 time series analysis, >50% decline in RVA cases were observed in two sites 310 in Kenya following Rotarix® introduction [22]. One of these sites was KCH. In 311 a previous analysis, using different viral detection assays, we also observed a 312 reduction in RVA among children <5 years old [12]. Our study did not find any 313 reduction in RVA prevalence among KCH children; however, there were some 314 key differences between our study and the previous studies. First, to detect 315 RVA infection, we used a TAC, which is considerably more sensitive than the 316 immunoassay (EIA) used in other studies [23]. Secondly, our study included 317 children up to 13 years of age, whereas the other studies included only 318 children under 5. In the previous Kenyan studies, children were sampled 319 between 2014 and 2017 [22] and 2003, 2013, 2016, and 2019 [12], which 320 does not overlap entirely with our study. The inclusion of older children and 321 the use of TAC provide evidence of a general prevalence of RVA in children, 322 as opposed to only the vaccine eligible children [24]. 323

324 The most frequently detected enteropathogens in our study in descending 325 order were; EAggEC, EPEC, enterovirus, RVA, parechovirus, Norovirus, 326 Cryptosporidium spp., Shigella spp. and Giardia lambia. In the Global Enteric 327 Multicenter Study of children <5 years-old, the most common pathogens 328 associated with diarrheal illness were RVA, enterotoxigenic *E. coli*, 329 Cryptosporidium spp., H. pylori, norovirus GII, Aeromonas spp., adenovirus, 330 EPEC, Shigella spp., C. difficile, and sapovirus [25]. Similarly, a study of 331 bacterial diarrheal infections in <5 year-olds in Western Kenya revealed that 332 E. coli and Shigella were the most common bacterial infections [26]. Our 333 previous study only examining a handful of viral pathogens among children <5 334 years at KCH demonstrated low prevalence of viral infections, with RVA and 335 adenovirus being the most common [12]. Although these studies took place in 336 different geographic regions and/or used different methods of pathogen 337 detection than ours, there is still consistency in the types of enteropathogens 338 observed.

339

340 There have been a very few studies focusing on changes in multiple

341 enteropathogen presentation after rotavirus vaccination [14, 22, 27-33]. We

342 observed a significant increase in prevalence of cytomegalovirus, EAggEC, D.

343 *fragilis* and *Strongyloides spp.* post-vaccination, as well as an increase in

344 enteropathogen co-infection, suggesting that a reduction in RVA could result

in a greater opportunity for other enteropathogens to fill the ecological niche

346 previously occupied by RVA. Interestingly, a study among hospitalized

347 children <5 years old in Tanzania examining the etiology of diarrheal illness

348 post-rotavirus vaccine found RVA, ETEC, Shigella, Cryptosporidium spp. and

astrovirus to be the five leading causes of diarrhea [34].

350

351 We demonstrated both a significant increase in prevalence of specific

352 enteropathogens as well as co-infection following introduction of the rotavirus

353 vaccine. While the detected enteropathogens could cause the diarrhea

observed in these hospitalized children, it is unclear which are symptomatic

355 illness versus long-term carriage. In order to understand changes in both

burden and disease following RVA vaccine introduction, repeated measures

357 studies on the same individuals including community controls are necessary.

358 Such studies will also be important in understanding the longer-term impact of 359 vaccination, carriage, and infection on children in LMIC settings.

360

361 This study had some limitations. Samples were collected more than two years 362 prior to analysis, which could compromise sample integrity. This setting might 363 have experienced a further change in enteropathogen burden since 2018 in 364 part due to the COVID-19 pandemic. However, this does not invalidate the 365 hypotheses generated by the findings regarding enteropathogen dynamics, 366 but rather suggests that continuous surveillance is critical for adapting and 367 maximizing diarrheal illness prevention. We did not analyze healthy controls 368 to adjust for the background prevalence of the detected enteropathogens in 369 this population. Of eligible children, 56.9% provided samples, which limited 370 our ability to assess the entire population of hospitalised children with 371 diarrhea. As a result of health worker industrial action in Kenya, enrollment 372 was interrupted five times [15]. In the pre-vaccine and post-vaccine 373 introduction years, the total nucleic acid extraction procedure varied, but we 374 did not expect this to have significantly impacted enteropathogen prevalence. 375 In spite of previous studies finding an association between pathogen 376 quantities and diarrhea attribution, we did not attempt to model these 377 associations in this study [21]. Finally, given the unbalanced time series 378 nature of this study it is difficult to draw conclusions about enteropathogen 379 dynamics following rotavirus vaccine introduction.

380

381 This study demonstrated increases in prevalence of EAEC, cytomegalovirus, 382 D. fragilis, Strongyloides spp. and co-infections post-rotavirus vaccination, but 383 little decrease in rotavirus infections in hospitalized children. Furthermore, we 384 observed increased detection of RVA by TAC compared to ELISA. These 385 findings highlight the need to use multiple detection arrays, such as TAC, for 386 regular surveillance of hospitalized children and community controls in order 387 to develop our understanding of differential observations of rotavirus vaccine 388 efficacy in settings with different RVA prevalence in order to tailor the best 389 vaccine approaches. Furthermore, such studies would provide insight into the 390 clinical implications of the frequent co-infections among children in order to 391 support high-quality interventions and individual patient care. Finally, our

- 392 study suggests the need for broad diagnostic approaches with high sensitivity
- 393 and specificity for enteropathogen surveillance and assessment of
- 394 enteropathogen vaccination efficacy.
- 395
- 396 **Acknowledgement.** We thank the study participants who provided the
- 397 samples and members of the Virus Epidemiology and Control (VEC) group at
- 398 KEMRI-Wellcome Trust Programme who collected the samples and
- 399 performed the laboratory processing. We thank Prof. Philip Bejon for
- 400 stimulating discussions about the work and comment provided on the initial
- 401 draft manuscript. This study is published with permission from Director
- 402 KEMRI.
- 403
- 404 **Funding.** This study was funded by the Cambridge-Africa ALBORADA
- 405 Research Fund . Dr Charles Agoti was supported by the Initiative to Develop
- 406 African Research Leaders (IDeAL) through the DELTAS Africa Initiative [DEL-
- 407 15-003]. The DELTAS Africa Initiative is an independent funding scheme of
- 408 the African Academy of Sciences (AAS)'s Alliance for Accelerating Excellence
- 409 in Science in Africa (AESA) and supported by the New Partnership for Africa's
- 410 Development Planning and Coordinating Agency (NEPAD Agency). Dr Lydia
- 411 Drumright was supported by the following funding sources during this study:
- 412 Medical Research Council (award # MR/S013164/1), the Alan Turing Institute
- through a Research Fellowship, the National Institutes for Health Research
- 414 (award # CDF-2011-04-017) and the Cambridge Biomedical Research
- 415 Center, the Economic and Social Science Research Council (award #
- 416 AH/R001952/1), and an Isaac Newton/Wellcome Trust ISSF award to
- 417 understand gastrointestinal infection epidemiology through use of this TAC.
- 418 The views expressed in this report are those of the authors and not
- 419 necessarily those of AAS, NEPAD Agency, The Wellcome, the UK
- 420 government.
- 421

#### 422 Data availability

- 423 The data described in this manuscript can be accessed by submitting a
- 424 request form to our Data Governance Committee (http://kemri-
- 425 wellcome.org/about-us/#ChildVerticalTab\_15).

#### 426

## 427 **REFERENCES**:

- 428 1. Troeger C, Blacker BF, Khalil IA, et al. Estimates of the global, regional, and
- 429 national morbidity, mortality, and aetiologies of diarrhoea in 195 countries: a
- 430 systematic analysis for the Global Burden of Disease Study 2016. The Lancet
- 431 Infectious Diseases **2018**; 18:1211-28.
- 432 2. Rogawski ET, Liu J, Platts-Mills JA, et al. Use of quantitative molecular diagnostic
- methods to investigate the effect of enteropathogen infections on linear growth inchildren in low-resource settings: longitudinal analysis of results from the MAL-ED
- 435 cohort study. Lancet Glob Health **2018**; 6:e1319-e28.
- 436 3. Steele AD, Victor JC, Carey ME, et al. Experiences with rotavirus vaccines: can we
- 437 improve rotavirus vaccine impact in developing countries? Human Vaccines &
  438 Immunotherapeutics **2019**; 15:1215-27.
- 439 4. Murunga N, G PO, Maia M, C NA. Effectiveness of Rotarix (®) vaccine in Africa in
- 441 meta-analysis. Wellcome Open Res **2020**; 5:187.
- 442 5. Willame C, Vonk Noordegraaf-Schouten M, Gvozdenovic E, et al. Effectiveness of
- 443 the Oral Human Attenuated Rotavirus Vaccine: A Systematic Review and Meta-444 analysis-2006-2016. Open Forum Infect Dis **2018**; 5:ofy292.
- 445 6. Walker JL, Andrews NJ, Atchison CJ, et al. Effectiveness of oral rotavirus
- 446 vaccination in England against rotavirus-confirmed and all-cause acute
- 447 gastroenteritis. Vaccine X **2019**; 1:100005.
- 448 7. Wandera EA, Mohammad S, Bundi M, et al. Impact of rotavirus vaccination on
- rotavirus and all-cause gastroenteritis in peri-urban Kenyan children. Vaccine **2017**;
- 450 35:5217-23.
- 451 8. Omore R, Khagayi S, Ogwel B, et al. Rates of hospitalization and death for all-cause
- 452 and rotavirus acute gastroenteritis before rotavirus vaccine introduction in Kenya,
- 453 2010–2013. BMC Infectious Diseases **2019**; 19:47.
- 454 9. Swierczewski BE, Odundo EA, Koech MC, et al. Surveillance for enteric pathogens
- in a case-control study of acute diarrhea in Western Kenya. Trans R Soc Trop Med
  Hyg 2013; 107:83-90.
- 457 10. Njuguna C, Njeru I, Mgamb E, et al. Enteric pathogens and factors associated with 458 acute bloody diarrhoea, Kenya. BMC Infect Dis **2016**; 16:477.
- 459 11. Florez ID, Niño-Serna LF, Beltrán-Arroyave CP. Acute Infectious Diarrhea and
- 460 Gastroenteritis in Children. Current Infectious Disease Reports **2020**; 22.
- 461 12. Lambisia AW, Onchaga S, Murunga N, Lewa CS, Nyanjom SG, Agoti CN.
- 462 Epidemiological Trends of Five Common Diarrhea-Associated Enteric Viruses Pre- and
- 463 Post-Rotavirus Vaccine Introduction in Coastal Kenya. Pathogens **2020**; 9.
- 464 13. Scott JA, Bauni E, Moisi JC, et al. Profile: The Kilifi Health and Demographic
- 465 Surveillance System (KHDSS). Int J Epidemiol **2012**; 41:650-7.
- 466 14. Khagayi S, Omore R, Otieno GP, et al. Effectiveness of Monovalent Rotavirus
- 467 Vaccine Against Hospitalization With Acute Rotavirus Gastroenteritis in Kenyan
- 468 Children. Clin Infect Dis **2020**; 70:2298-305.
- 15. Ong'ayo G, Ooko M, Wang'ondu R, et al. Effect of strikes by health workers on
- 470 mortality between 2010 and 2016 in Kilifi, Kenya: a population-based cohort
- 471 analysis. Lancet Glob Health **2019**; 7:e961-e7.

- 16. Marongiu L, Shain E, Drumright L, Lillestøl R, Somasunderam D, Curran MD.
- 473 Analysis of TaqMan Array Cards Data by an Assumption-Free Improvement of the
- 474 maxRatio Algorithm Is More Accurate than the Cycle-Threshold Method. PLOS ONE

475 **2016**; 11:e0165282.

- 476 17. Talbert A, Ngari M, Bauni E, et al. Mortality after inpatient treatment for diarrhea
- in children: a cohort study. BMC Medicine **2019**; 17.
- 478 18. Ruuska T, Vesikari T. Rotavirus disease in Finnish children: use of numerical
- scores for clinical severity of diarrhoeal episodes. Scand J Infect Dis **1990**; 22:259-67.
- 480 19. Heaney J, Rolfe K, Gleadall NS, Greatorex JS, Curran MD. Low-Density TaqMan®
- 481 Array Cards for the Detection of Pathogens. Methods in Microbiology 2015; 42:199-482 218.
- 483 20. Iturriza-Gómara M, Jere KC, Hungerford D, et al. Etiology of Diarrhea Among
- 484 Hospitalized Children in Blantyre, Malawi, Following Rotavirus Vaccine Introduction:
- 485 A Case-Control Study. The Journal of Infectious Diseases **2019**; 220:213-8.
- 486 21. Liu J, Platts-Mills JA, Juma J, et al. Use of quantitative molecular diagnostic
- 487 methods to identify causes of diarrhoea in children: a reanalysis of the GEMS case-488 control study. Lancet **2016**; 388:1291-301.
- 489 22. Otieno GP, Bottomley C, Khagayi S, et al. Impact of the Introduction of Rotavirus
- 490 Vaccine on Hospital Admissions for Diarrhea Among Children in Kenya: A Controlled
- 491 Interrupted Time-Series Analysis. Clin Infect Dis **2020**; 70:2306-13.
- 492 23. Moutelíková R, Dvořáková Heroldová M, Holá V, Sauer P, Prodělalová J. Human
- 493 rotavirus A detection: Comparison of enzymatic immunoassay and rapid
- 494 chromatographic test with two quantitative RT-PCR assays. Epidemiol Mikrobiol
- 495 Imunol **2018**; 67:110-3.
- 496 24. Soares-Weiser K, Maclehose H, Bergman H, et al. Vaccines for preventing
- 497 rotavirus diarrhoea: vaccines in use. Cochrane Database Syst Rev **2012**;
- 498 11:Cd008521.
- 499 25. Kotloff KL, Nasrin D, Blackwelder WC, et al. The incidence, aetiology, and adverse
- 500 clinical consequences of less severe diarrhoeal episodes among infants and children
- 501 residing in low-income and middle-income countries: a 12-month case-control study
- as a follow-on to the Global Enteric Multicenter Study (GEMS). Lancet Glob Health
  2019; 7:e568-e84.
- 504 26. RonoSalinah J, Rose K, Fabian E. Prevalence and clinico-demographic
- 505 characteristics associated with bacterial diarrhea among HIV positive and negative
- 506 children aged below five years at Moi Teaching and Referral Hospital, Kenya.
- 507 American Journal of Life Sciences **2014**; 2:1-8.
- 508 27. Aliabadi N, Antoni S, Mwenda JM, et al. Global impact of rotavirus vaccine
- 509 introduction on rotavirus hospitalisations among children under 5 years of age,
- 510 2008-16: findings from the Global Rotavirus Surveillance Network. Lancet Glob
- 511 Health **2019**; 7:e893-e903.
- 512 28. Burnett E, Jonesteller CL, Tate JE, Yen C, Parashar UD. Global Impact of Rotavirus
- 513 Vaccination on Childhood Hospitalizations and Mortality From Diarrhea. J Infect Dis 514 **2017**; 215:1666-72.
- 515 29. Lanzieri TM, Linhares AC, Costa I, et al. Impact of rotavirus vaccination on
- 516 childhood deaths from diarrhea in Brazil. Int J Infect Dis **2011**; 15:e206-10.
- 517 30. Patel MM, Steele D, Gentsch JR, Wecker J, Glass RI, Parashar UD. Real-world
- 518 impact of rotavirus vaccination. Pediatr Infect Dis J **2011**; 30:S1-5.

- 519 31. Quintanar-Solares M, Yen C, Richardson V, Esparza-Aguilar M, Parashar UD, Patel
- 520 MM. Impact of rotavirus vaccination on diarrhea-related hospitalizations among
- 521 children < 5 years of age in Mexico. Pediatr Infect Dis J **2011**; 30:S11-5.
- 522 32. Msimang VM, Page N, Groome MJ, et al. Impact of rotavirus vaccine on
- 523 childhood diarrheal hospitalization after introduction into the South African public
- immunization program. Pediatr Infect Dis J **2013**; 32:1359-64.
- 525 33. Weldegebriel G, Mwenda JM, Chakauya J, et al. Impact of rotavirus vaccine on
- rotavirus diarrhoea in countries of East and Southern Africa. Vaccine **2018**; 36:7124-
- 527 30.
- 528 34. Platts-Mills JA, Amour C, Gratz J, et al. Impact of Rotavirus Vaccine Introduction
- 529 and Postintroduction Etiology of Diarrhea Requiring Hospital Admission in Haydom,
- 530 Tanzania, a Rural African Setting. Clin Infect Dis **2017**; 65:1144-51.
- 531

# TABLES

Table 1. Demographic and clinical characteristics of the eligible, included and excluded participants and, among participants, pre-

Characteristic	All eligible (n=1250)	Included (n=718)	Excluded* (n=532)	Included vs Excluded	Pre-vaccine (n=241)	Post-vaccine (n=477)	Pre- vs Post- Vaccine
	n (%)	n (%)	n (%)	p-value	n (%)	n (%)	p-value
Sex (Male)	697 (55.8)	402 (56.0)	295 (55.5)	0.0850	139 (57.7)	263 (55.1)	0.517
Median age (IQR) in months	13.8 (8.2-24.6)	13.3 (8.0-23.0)	14.3 (8.5-26.6)	0.081	11.5 (6.8-21.5)	14.1 (8.5-24.2)	0.004
Age category (in months)				0.115			0.050
0-11	528 (42.2)	323 (45.0)	205 (38.5)		126 (52.3)	197 (41.3)	
12-23	402 (32.2)	224 (31.2)	178 (33.5)		65 (27.0)	159 (33.3)	
24-59	203 (16.2)	106 (14.8)	97 (18.2)		31 (12.9)	75 (15.7)	
>60	117 (9.4)	65 (9.1)	52 (9.8)		19 (7.9)	46 (9.6)	
Admission year				<0.001			
Year 2013	351 (28.1)	241 (33.6)	110 (20.7)		241 (100.0)	-	NA
Year 2016	348 (27.8)	245 (34.1)	103 (19.4)		-	252 (51.4)	
Year 2017	196 (15.7)	61 (8.5)	135 (25.4)		-	641(12.8)	
Year 2018	355 (28.4)	171 (23.8)	184 (34.6)		-	171 (35.9)	
HIV status				0.049			<0.001
Negative	994 (79.5)	565 (78.7)	429 (80.6)		171 (71.0)	394 (82.6)	
Infected/exposed	78 (6.24)	55 (7.7)	23 (4.3)		14 (5.8)	41 (8.6)	
Unknown	178 (14.2)	98 (13.7)	80 (15.0)		56 (23.2)	42 (8.8)	
Diarrhoea history at admission				0.497			0.371
Acute	1130 (90.4)	657 (91.5)	473 (88.9)		222 (92.1)	435 (91.2)	
Prolonged	79 (6.3)	40 (5.6)	39 (7.3)		10 (4.2)	30 (6.3)	
Persistent	10 (0.8)	5 (0.7)	5 (0.9)		3 (1.2)	2 (0.4)	
Chronic	31 (2.5)	16 (2.2)	16 (2.2)		6 (2.5)	10 (2.1)	
Bloody diarrhoea (n=1245)	75 (6.0)	42 (5.9)	33 (6.2)	0.796	17 (7.1)	25 (5.3)	0.328
Vomiting at admission	817 (65.4)	498 (69.4)	319 (60.0)	0.001	171 (71.0)	327(68.6)	0.510
Hospital length of stay							
Mean (SD#)	5.2 (5.0)	5.8 (5.4)	4.3 (4.3)	<0.001	5.5 (5.5)	5.9 (5.3)	0.317
Median (IQR)	4 (2-6)	4 (3-7)	3 (1-6)	<0.001	4 (2-7)	5 (3-7)	0.005
Vesikari Clinical Severity Score							
Mean (SD#)	11.4 (2.3)	11.5 (2.3)	11.3 (2.3)	0.183	11.7 (2.5)	11.4 (2.1)	0.062
Median (IQR)	11 (10-13)	11 (10-13)	11 (10-13)	0.182	11 (10-13)	11 (10-13)	0.289
Died before discharge	145 (11.6)	39 (5.4)	106 (19.9)	<0.001	8 (3.2)	31 (6.5)	0.076

vaccine versus the post-vaccine introduction period comparisons.

\* Due to insufficient stool sample provision

Table 2. Univariate and multivariate logistic regression comparing enteropathogen infection in the pre- vs post-rotavirus vaccine introduction periods (n=718)

			Prevalence	6			Univariate Logistic Regression	;	Multivariable <sup>#</sup> Logistic Regression	
		Total (n=718)	Pre-vaccir (n=241)	le	Post-vace (n=477)	cine				
Pathogen Type	Pathogen	n (%)	#+ve cases	Proportion (95% CI)	# +ve cases	Proportion (95% CI)	OR (95% CI)	p value	OR (95% CI)	p value
Virus	Adenovirus 40/41	49 (6.8)	14	5.8 (3.2-9.6)	35	7.3 (45.2-10.1)	1.28 (0.68, 2.44)	0.444	1.16 (0.60, 2.24)	0.667
	Any Adenovirus	104 (14.5)	28	11.6 (7.9-16.4)	76	15.9 (12.8- 19.5)	1.44 (0.91, 2.29)	0.122	1.33 (0.82, 2.13)	0.247
	Rotavirus group A	178 (24.8)	66	27.4 (21.9-33.5)	112	23.5 (19.8- 27.6)	0.81 (0.57, 1.16)	0.253	0.97 (0.66, 1.42)	0.879
	Norovirus GI/GII	103 (14.4)	27	11.2 (7.5-15.9)	76	15.9 (12.8- 19.5)	1.50 (0.94, 2.40)	0.089	1.53 (0.94, 2.49)	0.086
	Astrovirus	34 (4.7)	12	5.0 (2.6-8.5)	22	4.6 (2.9-7.0)	0.81 (0.57, 1.16)	0.253	0.97 (0.66, 1.42)	0.879
	Sapovirus	38 (5.3)	19	7.6 (4.8-1.0)	19	4.0 (2.4-6.2)	0.49 (0.25, 0.93)	0.030	0.64 (0.32, 1.28)	0.205
	Enterovirus	19 (26.9)	65	27.0 (21.5-33.0)	128	26.8 (23.0- 31.1)	0.99 (0.70, 1.41)	0.969	0.97 (0.67, 1.39)	0.851
	Parechovirus	119 (16.6)	47	19.5 (14.7-25.1)	72	15.1 (12.0- 18.6)	0.73 (0.49, 1.10)	0.135	0.73 (0.48, 1.12)	0.158
	Hepatitis A virus	11 (1.5)	1	0.4 (0.0-2.3)	10	2.0 (1.0-3.8)	5.14 (0.65, 40.38)	0.120	4.00 (0.50, 31.77)	0.190
	Hepatitis E virus	1 (0.14)	0	0 (0-1.5)	1	0.2 (0.0-1.2)	NA		NA	
	Cytomegalovirus	57 (7.9)	10	4.2 (2.0-7.5)	47	9.9 (7.3-12.9)	2.53 (1.25, 5.09)	0.010	2.81 (1.36, 5.81)	0.005
Bacteria	Enteropathogenic <i>E.</i> coli	217 (30.2)	68	28.2 (22.6-34.4)	149	31.2 (27.1- 35.6)	1.16 (0.82, 1.63)	0.405	1.24 (0.87, 1.76)	0.240
	Enteroaggregative E. coli	302 (42.1)	86	35.7 (29.6-42.1)	216	45.3 (40.8- 50.0)	1.49 (1.08, 2.05)	0.014	1.58 (1.13, 2.20)	0.007
	Verotoxogenic E. coli	4 (0.6)	0	0 (0-1.5)	4	0.8 (0.2-2.1)	NA	0.176	NA	
	Shigella spp	83 (11.6)	21	8.7 (5.5-13.0)	62	13.0 (10.2- 16.4)	1.57 (0.93, 2.64)	0.092	1.49 (0.87, 2.54)	0.144
	C. perfringens/difficile	33 (4.6)	8	3.3 (1.4-6.4)	25	5.2 (3.4-7.6)	1.61 (0.72, 3.63)	0.250	1.51 (0.66, 3.47)	0.334
	Salmonella spp	15 (2.1)	5	2.0 (0.7-4.8)	10	2.1 (1.0-3.8)	1.01 (0.34, 2.99)	0.985	1.10 (0.35, 3.42)	0.877
	C. jejuni/coli	56 (7.8)	17	7.1 (4.2-11.1)	39	8.2 (5.9-11.0)	1.17 (0.65, 2.12)	0.597	1.13 (0.61, 2.07)	0.706
	V. cholerae	11 (1.53)	0	0 (0-1.5)	11	2.3 (1.2-4.1)	NA		NA	
	Aeromonas spp	7 (1.0)	3	1.3 (0.3-3.6)	4	0.8 (0.2-2.1)	0.67 (0.15, 3.02)	0.603	0.74 (0.15, 3.56)	0.707
	Y. enterocolitica	2 (0.3)	0	0 (0-1.5)	2	0.3 (0.0-1.5)	NA		NA	
Protozoa	Cryptosporidium spp	98 (13.7)	28	11.6 (7.9-16.4)	70	14.7 (11.6- 18.2)	1.31 (0.82, 2.09)	0.261	1.36 (0.83, 2.20)	0.219
	D.fragilis	42 (5.9)	5	2.0 (0.7-4.8)	37	7.8 (5.5-10.5)	3.97 (1.54, 10.23)	0.004	3.90 (1.49, 10.21)	0.006
	G. lambia	81 (11.3)	27	11.2 (7.5-15.9)	54	11.3 (8.6-14.5)	1.01 (0.62, 1.65)	0.963	0.96 (0.57, 1.61)	0.881
	C. belli	1 (0.14)	0	0 (0-1.5)	1	0.4 (0.0-1.2)	NA		NA	
	C. cayetanensis	2 (0.3)	2	0.8 (0.1-3.0)	0	0.0 (0.0-0.7)	NA	0.110	NA	
Helminth	Strongyloides spp.	19 (2.7)	2	0.8 (0.1-3.0)	17	3.6 (2.1-5.7)	4.42 (1.01, 19.27)	0.048	4.60 (1.03, 20.55)	0.046

<sup>#</sup> All models are adjusted for age, vesikari score, fatality, length of stay (LOS), HIV status, and gender; due to high coinfection rates, enteropathogens aare modelled separately.

## FIGURES LEGENDS

**Figure 1.** Prevalence of enteropathogens in stool samples from 718 children hospitalised at KCH at different PCR cycle threshold (Ct) cut-offs. The bars represent organism type and include 95% confidence interval errors bars for the proportions. Panel (a) prevalence of the detected enteropathogens when applying a Ct cut-off of ≤40 to define positives. Panel (b) prevalence of the detected enteropathogens when applying a Ct cut-off ≤35 to define positives. Panel (c) prevalence of detected the enteropathogens when applying a Ct cut-off ≤30 to define positives.

**Figure 2.** Boxplots examining the relationship between the observed RVA detection cycle threshold (Ct) from TAC assay and (a) previous enzyme-linked immunosorbent assay (ELISA) result on the same samples, (b) period of sample collection, (c) rotavirus vaccination status, and (d) age group in stool samples from 718 children at KCH. P-values are derived from an independent t-test, one-way ANOVA, and where applicable Kruskal Wallis was used.

## Figure 1.





